BHC Stock Summary and Trading Ideas (Bausch Health Companies | NYSE:BHC)

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Bausch Health Companies trades on the NYSE stock market under the symbol BHC.

As of December 30, 2025, BHC stock price declined to $6.99 with 1,225,505 million shares trading.

BHC has a beta of 0.97, meaning it tends to be less sensitive to market movements. BHC has a correlation of 0.05 to the broad based SPY ETF.

BHC has a market cap of $2.59 billion. This is considered a Mid Cap stock.

Last quarter Bausch Health Companies reported $3 billion in Revenue and $1.16 earnings per share. This beat revenue expectation by $66 million and exceeded earnings estimates by $.10.

In the last 3 years, BHC traded as high as $11.46 and as low as $3.96.

The top ETF exchange traded funds that BHC belongs to (by Net Assets): DFIS, PPH, DFIC, DISV, DFAX.

BHC has underperformed the market in the last year with a price return of -8.6% while the SPY ETF gained +16.7%. However, in the short term, BHC had mixed performance relative to the market. It has outperformed in the last 3 months, returning +8.0% vs +3.8% return in SPY. But in the last 2 weeks, BHC shares have been beat by the market, returning +1.2% compared to an SPY return of +1.2%.

BHC support price is $6.91 and resistance is $7.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BHC shares will trade within this expected range on the day.